AIFORIA TECHNOLOGIES OYJ Aiforia Technologies Plc entered into an exclusive licensing agreement with the Mayo Clinic in the United States to globally commercialize an AI model that improves prediction of colorectal cancer recurrence. The AI model was developed in collaboration with the Mayo Clinic. The AI model identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for colorectal cancer treatment decisions. The co-developed prognostic AI model identifies 15 different tissue characteristics in colorectal cancer patient samples, and combined with two other clinical parameters, it produces a colorectal cancer recurrence risk score. For example, an AI model can identify patients who may not need chemotherapy because the probability of cancer recurrence is low.
It may also help to identify those patients who are at high risk of relapse and may benefit from more intensive treatment or follow-up. The implementation of an artificial intelligence model may save significant sums in treatment costs, when expensive chemotherapy drugs are targeted more efficiently than at present. The most important benefit from the patient's point of view is the reduction of chemotherapy without worsening the treatment results.
In practice, this can mean significant reduction of harmful side effects. The functionality of the AI model has been proven retrospectively in several independent patient sample cohorts. The Aiforia collaboration with the Mayo Clinical began with the implementation of the Aiforia AI-assisted image analysis software in pathology research already in 2020.
In the translational research, more than 70 Mayo Clinic pathologists use the Aiforia Create tool. for creating AI models for their research studies, which aim to utilize the models in clinical work later. There are more than 30 ongoing research projects utilizing the Aiforia technology at the Mayo Clinic.
An important milestone in the collaboration was reached in spring 2023, when the Mayo Clinic began diagnosing clinical patient samples with Aiforia's software.
